NCT06981325
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
REGN — REGENERON PHARMACEUTICALS, INC.
Phase 2
• Basal Cell Carcinoma (BCC), First Line Treatment
TL;DR
Locations updated — PHASE2
What changed
Recent events (last 90 days)
What to check next
- Review CT.gov update history and company disclosures for context.
- Verify whether registry updates lag press releases.